Analyzing Frontline Options for Patients With Bladder Cancer
Thomas Powles, MD, shares his advice for community oncologists treating patients with bladder cancer in the frontline setting. According to Powles, this is a setting where there is a lot of uncertainty that can make decision making difficult.
Thomas Powles, MD, Barts Cancer Institute, shares his advice for community oncologists treating patients with bladder cancer in the frontline setting. According to Powles, this is a setting where there is a lot of uncertainty that can make decision making difficult.
Powles advises clinicians treat patients who are biomarker-positive with immunotherapy, particularly those who will benefit from chemotherapy if the immunotherapy does not work. This also includes patients who have relatively low aggressive disease or rapidly progressive liver metastases.
For patients with slow progressive bladder cancer, clinical trials are looking for more attractive approaches than chemotherapy for these patients. While data are still not available from randomized trials, it is best to air on the safe side with chemotherapy treatment.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
